Form 4: DENTSPLY SIRONA Director Betsy Holden Receives Significant RSU Grant

DENTSPLY SIRONA Inc. Director Betsy D. Holden was granted 13,880 Restricted Stock Units (RSUs) on May 22, 2025, increasing her beneficial ownership to 52,753.365 shares.

Summary

• Betsy D. Holden, a Director of DENTSPLY SIRONA Inc. (XRAY), acquired 13,880 shares of common stock.
• The acquisition occurred on May 22, 2025, and was a grant of Restricted Stock Units (RSUs) with a transaction price of $0.
• These 13,880 RSUs are scheduled to vest in full one year from the grant date.
• Following this transaction, Ms. Holden's beneficial ownership of DENTSPLY SIRONA common stock increased to 52,753.365 shares.

Sentiment

Score: 7

Explanation: The grant of RSUs to a director is a positive signal of continued alignment between management and shareholder interests, and is a standard form of compensation. It does not indicate any immediate operational or financial issues.

Positives

• The grant of Restricted Stock Units to a director aligns management's interests with those of shareholders, as the value of the grant is directly tied to the company's stock performance.
• The increase in beneficial ownership by a director demonstrates continued commitment and confidence in the company's future.

Negatives

• No specific negatives are identified in this Form 4 filing, which primarily reports a routine insider equity compensation transaction.

Risks

• The ultimate value of the granted Restricted Stock Units is contingent upon the future performance of DENTSPLY SIRONA's common stock until the vesting date.

Future Outlook

The 13,880 Restricted Stock Units granted to Director Betsy D. Holden are scheduled to vest in full one year from the grant date of May 22, 2025, indicating a future equity inflow for the director contingent on continued service.

Industry Context

This filing is a routine insider transaction report for a director's equity compensation. Such RSU grants are common practice in publicly traded companies across various industries, including healthcare and dental technology, to align director and executive interests with shareholder value and to aid in retention.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) as part of director compensation is a standard practice across many industries, including the healthcare and dental technology sectors where DENTSPLY SIRONA operates.
• The vesting schedule of one year for director equity grants is a common approach, aiming to retain talent and align long-term interests.
• Comparable companies in the medical device and dental supply industry, such as Align Technology (ALGN) or Zimmer Biomet (ZBH), also commonly utilize RSU grants for their directors and executives, though specific grant amounts and vesting terms vary based on company-specific compensation policies and performance.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's interests with shareholders, as the value of the grant is tied to the company's stock performance. It also represents a minor form of potential future dilution upon vesting.

Next Steps

• The 13,880 Restricted Stock Units are expected to vest on May 22, 2026.

Key Dates

Recommendation

Keywords

DENTSPLY SIRONA, XRAY, Form 4, Insider Transaction, Restricted Stock Units, RSU Grant, Director Compensation, Beneficial Ownership, Equity Compensation